A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and effic...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Souza, Anita, Shah, Nina, Rodriguez, Cesar, Voorhees, Peter M., Weisel, Katja, Bueno, Orlando F., Pothacamury, Rajvineeth K., Freise, Kevin J., Yue, Susan, Ross, Jeremy A., Polepally, Akshanth R., Talati, Chetasi, Lee, Shane, Jin, Ziyi, Buelow, Ben, Vij, Ravi, Kumar, Shaji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622641/
https://www.ncbi.nlm.nih.gov/pubmed/36029527
http://dx.doi.org/10.1200/JCO.22.01504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622641/
https://www.ncbi.nlm.nih.gov/pubmed/36029527
http://dx.doi.org/10.1200/JCO.22.01504

Ejemplares similares